Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.

Yurgelun MB, Masciari S, Joshi VA, Mercado RC, Lindor NM, Gallinger S, Hopper JL, Jenkins MA, Buchanan DD, Newcomb PA, Potter JD, Haile RW, Kucherlapati R, Syngal S; Colon Cancer Family Registry.

JAMA Oncol. 2015 May;1(2):214-21.

2.

The spectrum of FBN1, TGFβR1, TGFβR2 and ACTA2 variants in 594 individuals with suspected Marfan Syndrome, Loeys-Dietz Syndrome or Thoracic Aortic Aneurysms and Dissections (TAAD).

Lerner-Ellis JP, Aldubayan SH, Hernandez AL, Kelly MA, Stuenkel AJ, Walsh J, Joshi VA.

Mol Genet Metab. 2014 Jun;112(2):171-6. doi: 10.1016/j.ymgme.2014.03.011. Epub 2014 Apr 2.

PMID:
24793577
3.

The introduction of systematic genomic testing for patients with non-small-cell lung cancer.

Cardarella S, Ortiz TM, Joshi VA, Butaney M, Jackman DM, Kwiatkowski DJ, Yeap BY, Jänne PA, Lindeman NI, Johnson BE.

J Thorac Oncol. 2012 Dec;7(12):1767-1774. doi: 10.1097/JTO.0b013e3182745bcb.

4.

The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.

Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.

Clin Cancer Res. 2012 Aug 15;18(16):4406-14. doi: 10.1158/1078-0432.CCR-12-0357. Epub 2012 Jun 25.

5.

The GeneInsight Suite: a platform to support laboratory and provider use of DNA-based genetic testing.

Aronson SJ, Clark EH, Babb LJ, Baxter S, Farwell LM, Funke BH, Hernandez AL, Joshi VA, Lyon E, Parthum AR, Russell FJ, Varugheese M, Venman TC, Rehm HL.

Hum Mutat. 2011 May;32(5):532-6. doi: 10.1002/humu.21470. Epub 2011 Mar 22.

6.

EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.

Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, Lynch TJ, Sequist LV.

Neuro Oncol. 2010 Nov;12(11):1193-9. doi: 10.1093/neuonc/noq076. Epub 2010 Jul 13.

7.

A restricted spectrum of NRAS mutations causes Noonan syndrome.

Cirstea IC, Kutsche K, Dvorsky R, Gremer L, Carta C, Horn D, Roberts AE, Lepri F, Merbitz-Zahradnik T, König R, Kratz CP, Pantaleoni F, Dentici ML, Joshi VA, Kucherlapati RS, Mazzanti L, Mundlos S, Patton MA, Silengo MC, Rossi C, Zampino G, Digilio C, Stuppia L, Seemanova E, Pennacchio LA, Gelb BD, Dallapiccola B, Wittinghofer A, Ahmadian MR, Tartaglia M, Zenker M.

Nat Genet. 2010 Jan;42(1):27-9. doi: 10.1038/ng.497. Epub 2009 Dec 6.

8.

Fluconazole analogues containing 2H-1,4-benzothiazin-3(4H)-one or 2H-1,4-benzoxazin-3(4H)-one moieties, a novel class of anti-Candida agents.

Borate HB, Maujan SR, Sawargave SP, Chandavarkar MA, Vaiude SR, Joshi VA, Wakharkar RD, Iyer R, Kelkar RG, Chavan SP, Kunte SS.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):722-5. doi: 10.1016/j.bmcl.2009.11.071. Epub 2009 Dec 4.

PMID:
19963383
9.

Platform evaluation for rapid genotyping of CYP2C9 and VKORC1 alleles.

Joshi VA, Duffy E, Funke BH, Farwell LM, Mancini-Dinardo D, Kucherlapati R.

Per Med. 2009 Jul;6(4):449-457. doi: 10.2217/pme.09.8.

PMID:
29783542
10.

DNA sequencing of cancer-related genes for biomarker discovery.

Farwell LM, Joshi VA.

Methods Mol Biol. 2009;520:205-20. doi: 10.1007/978-1-60327-811-9_15.

PMID:
19381957
11.

EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer.

Smouse JH, Cibas ES, Jänne PA, Joshi VA, Zou KH, Lindeman NI.

Cancer. 2009 Feb 25;117(1):67-72. doi: 10.1002/cncy.20011.

12.

Further insight into the markers of methotrexate resistance in childhood acute lymphoblastic leukemia patients.

Krajinovic M, Brukner I, Iqbal O, Bender R, Joshi VA, John T, Tsao MS, Liu G.

Per Med. 2008 Jul;5(4):325-329. doi: 10.2217/17410541.5.4.325. No abstract available.

13.

Genetics and genomics in the practice of medicine.

Joshi VA, Kucherlapati R.

Gastroenterology. 2008 May;134(5):1284-8. doi: 10.1053/j.gastro.2008.03.046. Review. No abstract available.

PMID:
18471501
14.

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.

J Clin Oncol. 2008 May 20;26(15):2442-9. doi: 10.1200/JCO.2007.14.8494. Epub 2008 May 5. Erratum in: J Clin Oncol. 2008 Jul 10;26(20):3472.

PMID:
18458038
15.

Selection of a platform for mutation detection.

Joshi VA, Mancini-DiNardo D, Funke BH.

Curr Protoc Hum Genet. 2008 Jan;Chapter 7:Unit 7.15. doi: 10.1002/0471142905.hg0715s56.

PMID:
18428425
16.

Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies.

Joshi VA, Kucherlapati R.

Pharmacogenomics. 2007 Sep;8(9):1211-20. Review.

PMID:
17924836
17.

Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.

Finberg KE, Sequist LV, Joshi VA, Muzikansky A, Miller JM, Han M, Beheshti J, Chirieac LR, Mark EJ, Iafrate AJ.

J Mol Diagn. 2007 Jul;9(3):320-6.

18.

Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.

Sequist LV, Joshi VA, Jänne PA, Muzikansky A, Fidias P, Meyerson M, Haber DA, Kucherlapati R, Johnson BE, Lynch TJ.

Oncologist. 2007 Jan;12(1):90-8.

PMID:
17285735
19.

Germline gain-of-function mutations in SOS1 cause Noonan syndrome.

Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, Li L, Yassin Y, Tamburino AM, Neel BG, Kucherlapati RS.

Nat Genet. 2007 Jan;39(1):70-4. Epub 2006 Dec 3.

PMID:
17143285
20.

Lung cancer genetics and pharmacogenomics.

Joshi VA, Kucherlapati R.

Cytogenet Genome Res. 2006;115(3-4):298-302.

PMID:
17124413
21.

Epidermal growth factor receptor mutation testing in the care of lung cancer patients.

Sequist LV, Joshi VA, Jänne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4403s-4408s. Review.

22.

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA.

Clin Cancer Res. 2006 Jul 1;12(13):3908-14.

23.

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.

Jänne PA, Borras AM, Kuang Y, Rogers AM, Joshi VA, Liyanage H, Lindeman N, Lee JC, Halmos B, Maher EA, Distel RJ, Meyerson M, Johnson BE.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):751-8.

24.

Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck.

Wirth LJ, Haddad RI, Lindeman NI, Zhao X, Lee JC, Joshi VA, Norris CM Jr, Posner MR.

J Clin Oncol. 2005 Oct 1;23(28):6976-81. Epub 2005 Sep 19.

PMID:
16172459
25.

Removal of fluoride from fluoride contaminated industrial waste water by electrolysis.

Joshi VA, Nanoti MV.

Ann Chim. 2003 Sep-Oct;93(9-10):753-60.

PMID:
14672366
26.

Performance evaluation of reverse osmosis desalination plants for rural water supply in a developing country--a case study.

Kelkar PS, Joshi VA, Ansari MH, Manivel U.

Environ Monit Assess. 2003 Dec;89(3):243-61.

PMID:
14632093

Supplemental Content

Loading ...
Support Center